Glucagon-like peptide containing pathways in the regulation of feeding behaviour

The pre-proglucagon derived peptides, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are both involved in a wide variety of peripheral functions, such as glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. Pre-proglucagon is also found in the brainstem in a small population of nerve cells in the nucleus of the solitary tract (NTS) that process the pre-propeptide as in the gut to yield GLP-1 and GLP-2. GLP-1 containing nerve fibres and the GLP-1 receptor are found predominantly in hypothalamic midline nuclei. GLP-1 given centrally to naive rats results in a marked induction of c-Fos protein in the supraoptic nucleus, paraventricular nucleus of the hypothalamus (PVN) and central nucleus of the amygdala, but only a moderate increase in the arcuate nucleus. The pattern of c-Fos activation is compatible with the appetite suppressing effects of GLP-1. This anorectic effect of GLP-1 appears to be mediated by the PVN, as direct injections of GLP-1 into this nucleus cause anorexia without concomitant taste aversion, suggesting a specific action upon neuronal circuits involved in the regulation of feeding. Recent experiments have also shown that GLP-1 is implicated in mediating signals from the gastrointestinal tract pertaining to discomfort and malaise. The distribution of the co-localised peptide, GLP-2, displays a perfect overlap with GLP-1 in the CNS with the highest concentration in the diffuse ventral part of the dorsomedial nucleus (DMHv). In contrast to the widely distributed GLP-1 receptor mRNA, GLP-2 receptor mRNA is exclusively expressed in the compact part of the DMH (DMHc). Interestingly, the DMHc is also the only nucleus responding to central administration of GLP-2 with a significant increase in the number of c-Fos positive cells. When injected into the lateral ventricle, GLP-2 has a marked inhibitory effect on feeding. The effect of GLP-2 on feeding is both behaviourally and pharmacologically specific. Future experiments will elucidate whether or not GLP-1 and GLP-2 are involved in the long-term or short-term regulation of feeding behaviour and hence have an impact on bodyweight.

[1]  S. Bloom,et al.  Leptin interacts with glucagon‐like peptide‐1 neurons to reduce food intake and body weight in rodents , 1997, FEBS letters.

[2]  L. Bellinger,et al.  The Dorsomedial Hypothalamic Nucleus Revisited: 1998 Update , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[3]  D. Drucker,et al.  New frontiers in the biology of GLP-2 , 2000, Regulatory Peptides.

[4]  P. J. Larsen,et al.  Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. , 1998, Diabetes.

[5]  J. Holst.  Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. , 1999, Current medicinal chemistry.

[6]  M. Phillips.  Functions of angiotensin in the central nervous system. , 1987, Annual review of physiology.

[7]  S. Grinstein,et al.  Identification of Glucagon-like Peptide-2 (GLP-2)-activated Signaling Pathways in Baby Hamster Kidney Fibroblasts Expressing the Rat GLP-2 Receptor* , 1999, The Journal of Biological Chemistry.

[8]  M. Smith,et al.  Neuropeptide Y (NPY) neurons in the arcuate nucleus (ARH) and dorsomedial nucleus (DMH), areas activated during lactation, project to the paraventricular nucleus of the hypothalamus (PVH) , 1998, Regulatory Peptides.

[9]  B. Yeğen,et al.  Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. , 1997, The American journal of physiology.

[10]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[11]  P. J. Larsen,et al.  Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. , 1995, Neuroendocrinology.

[12]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[13]  R. Cone,et al.  Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. , 1997, Molecular endocrinology.

[14]  J. Holst,et al.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. , 1997, Gut.

[15]  S. Woods,et al.  University of Groningen Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats , 2002 .

[16]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[17]  P. J. Larsen,et al.  The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake , 2000, Nature Medicine.

[18]  P. J. Larsen,et al.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. , 1996, The American journal of physiology.

[19]  P. Shughrue,et al.  Distribution of pre‐pro‐glucagon and glucagon‐like peptide‐1 receptor messenger RNAs in the rat central nervous system , 1999, The Journal of comparative neurology.

[20]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.